Loading...

ENGN ENGENE HOLDINGS INC Product Launches 8-K Filing

NGN

NGN

ENGENE HOLDINGS INC

(ENGN)

2024 8-K

Sales Agreement

Financial Results Announced

Loan Agreement Update

Loan Agreement Update

Financial Results Report

Public Offering Announced

Clinical Trial Update

Board Amendment Approved

Board Appointments

Management Change

Financial Results Report

Enrollment Milestone

Financial Statements

Equity Offerings

Geographic Expansion

Financial Results

Share Sale Agreement

Loan Agreement Update

Private Placement

Leadership Changes

Quarterly Results

Corporate Update

External Links:

enGene Holdings Inc. announced preliminary data from its LEGEND study showing that 71% of patients with high-risk bladder cancer achieved a complete response to their investigational product, detalimogene voraplasmid, with a median age of 74 years and a median of 11 prior BCG treatments.

AI Assistant

ENGENE HOLDINGS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.